Non-small cell lung cancer

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer diagnoses and includes histologic subtypes such as adenocarcinoma and squamous cell carcinoma. Staging, biomarker testing, and line of therapy determine treatment selection. Clinical practice evolves through published trials, FDA label changes, and guideline updates—not through static market estimates on this page.

The NSCLC treatment landscape spans surgery, radiation, chemotherapy, targeted therapies for actionable mutations (EGFR, ALK, ROS1, KRAS, and others), and immunotherapies. PD-1/PD-L1 inhibitors appear across multiple lines in FDA databases. Biomarker testing is standard of care for identifying eligible populations. This page avoids unsourced market size figures; consult epidemiology primary literature for incidence data.

• Merck
• Bristol Myers Squibb
• AstraZeneca

• Drug profileKeytruda (pembrolizumab)
• Drug profileOpdivo (nivolumab)

• FDA supplemental approvals continue to modify checkpoint inhibitor labels in early and metastatic NSCLC.
• ClinicalTrials.gov registers perioperative immunotherapy trials across multiple sponsors.
• SEC filings from major oncology companies reference NSCLC as a priority lifecycle indication.